tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

OSTX Stock Latest News

Promising Regulatory Progress and Market Potential Justify Buy Rating for OS Therapies’ OST-HER2
RatingsPromising Regulatory Progress and Market Potential Justify Buy Rating for OS Therapies’ OST-HER2
3d ago
OSTX
Strategic Regulatory Advances and Promising Clinical Data Drive Buy Rating for OS Therapies
PremiumRatings
Strategic Regulatory Advances and Promising Clinical Data Drive Buy Rating for OS Therapies
13d ago
OSTX
OS Therapies Files Prospectus for Stock Resale
PremiumCompany Announcements
OS Therapies Files Prospectus for Stock Resale
13d ago
8K
OSTX
Optimistic Buy Rating on OS Therapies Inc. Amid Promising Clinical Advancements
PremiumRatings
Optimistic Buy Rating on OS Therapies Inc. Amid Promising Clinical Advancements
27d ago
OSTX
OS Therapies Raises $3.7M for OST-HER2 Launch
PremiumCompany Announcements
OS Therapies Raises $3.7M for OST-HER2 Launch
1M ago
8K
OSTX
OS Therapies Ends Equity Agreement with Square Gate
PremiumCompany AnnouncementsOS Therapies Ends Equity Agreement with Square Gate
2M ago
8K
OSTX
OS Therapies Reports Progress in Osteosarcoma Treatment
Premium
Company Announcements
OS Therapies Reports Progress in Osteosarcoma Treatment
2M ago
OSTX
OS Therapies Inc.: Promising OST-HER2 Developments and Strategic FDA Milestones Drive Buy Rating
Premium
Ratings
OS Therapies Inc.: Promising OST-HER2 Developments and Strategic FDA Milestones Drive Buy Rating
2M ago
OSTX
OS Therapies Updates Quorum Rules for Shareholder Meetings
PremiumCompany Announcements
OS Therapies Updates Quorum Rules for Shareholder Meetings
2M ago
8K
OSTX
OS Therapies Delays Q2 2025 Financial Report
PremiumCompany Announcements
OS Therapies Delays Q2 2025 Financial Report
2M ago
OSTX
OS Therapies files $100M mixed securities shelf
PremiumThe Fly
OS Therapies files $100M mixed securities shelf
2M ago
OSTX
Promising Phase 2b Results and Regulatory Advancements Drive Buy Rating for OS Therapies
PremiumRatings
Promising Phase 2b Results and Regulatory Advancements Drive Buy Rating for OS Therapies
2M ago
OSTX
OS Therapies files to sell 3.76M shares of common stock for holders
PremiumThe FlyOS Therapies files to sell 3.76M shares of common stock for holders
2M ago
OSTX
OS Therapies CEO Paul Romness sees ‘huge upside potential’
Premium
The Fly
OS Therapies CEO Paul Romness sees ‘huge upside potential’
3M ago
OSTX
OS Therapies hopes to become commercial biotech in early 2026, CEO says
Premium
The Fly
OS Therapies hopes to become commercial biotech in early 2026, CEO says
3M ago
OSTX
Romness sees potential FDA approval, PVR as key to OS Therapies stock
PremiumThe Fly
Romness sees potential FDA approval, PVR as key to OS Therapies stock
3M ago
OSTX
Meet OS Therapies: Fly exclusive interview with CEO Paul Romness
PremiumThe Fly
Meet OS Therapies: Fly exclusive interview with CEO Paul Romness
3M ago
OSTX
OS Therapies Raises $4.2M Through Warrant Exercise
PremiumCompany Announcements
OS Therapies Raises $4.2M Through Warrant Exercise
3M ago
8K
OSTX
OS Therapies Inc.: Promising Cancer Immunotherapy and Strategic Regulatory Advancements Support Buy Rating
PremiumRatings
OS Therapies Inc.: Promising Cancer Immunotherapy and Strategic Regulatory Advancements Support Buy Rating
3M ago
OSTX
OS Therapies granted End of Phase 2 Meeting by FDA to review OST-HER2 program
PremiumThe FlyOS Therapies granted End of Phase 2 Meeting by FDA to review OST-HER2 program
3M ago
OSTX
Positive Buy Rating for OS Therapies Driven by Promising Phase 2b Trial Results and Regulatory Progress
Premium
Ratings
Positive Buy Rating for OS Therapies Driven by Promising Phase 2b Trial Results and Regulatory Progress
3M ago
OSTX
OS Therapies reports ‘positive’ results from Phase 2b trial of OST-HER2
Premium
The Fly
OS Therapies reports ‘positive’ results from Phase 2b trial of OST-HER2
4M ago
OSTX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >